Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1713)	12/5/2006 3:56:54 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

It seems that Tim Barabe & other insiders that have been consistently buying some shares of ARQL this Yr.were on the right tract.<g> The stock today continued on the upmove that started on Nov.10 from the 4.05 level & seems that will close near its intraday H. bigcharts.marketwatch.com That was in spite of the poor results on the 3rdQ, the expected loss of close to $1/shr this Yr. vs. the loss of $0.22/shr in 2005 & the expected loss of $1.55/shr in 2007.<g> But on Nov.9 was when it announced that ARQ 501 had good potential when used in combination with chemotherapy agents, as shown from he results of the P1b in which ARQ 501 was used in combination with docetaxel. Bernard

To: Jibacoa who wrote (1713)	2/8/2007 9:04:30 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ASTM Has closed its Jan 12 DG & seems to have found support at the $1.35 level. It announced last month that it was a starting a trial of its TRCs in osteonecrosis. The stock needs to close above $1.80 for its longer term chart to start looking better. <g> Bernard

To: Jibacoa who wrote (1713)	5/17/2007 10:31:17 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GERN Opened with an UG after announcing that its scientists and collaborators at the University of Alberta have differentiated human embryonic stem cells into islet-like clusters that secrete insulin in response to elevated glucose levels. biz.yahoo.com The stock is up more than 8% as it traded above the $9 level at 10:24AM bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1713)	10/3/2007 4:05:09 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

STEM is moving up after finding support at the $2 level.<g> bigcharts.marketwatch.com The stock needs to close above 3.20 in order to start getting off the DT coming from its July 2005 at 6.58 but it has a good amount of resistance at $3.65 & $4 levels. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1713)	10/10/2007 11:49:24 PM
From: Jibacoa	Respond to of 3722

MCET was up 271% today & volume expanded to 4,157,520 about 39x its ADV.It was more than 500% at the time of its intraday H (10:50AM).<g> bigcharts.marketwatch.com At its intraday H it was able to briefly test its March Hs.<g> bigcharts.marketwatch.com Will see if Corning will be able to do for the company what PFE & BMY haven't, that is, to help it get over the $1 level.<g> bigcharts.marketwatch.com MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated Wednesday October 10, 10:23 am ET Corning to Use Cell Lines for Assay Development, Biomarker Identification and ADME/Tox Applications LINCOLN, R.I., Oct. 10 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET - News), entered into a worldwide exclusive license and technology purchase agreement with Corning Incorporated of Corning, NY concerning the Company's Fa2N-4 immortalized adult human liver cell lines. Corning paid MultiCell a license fee, and has agreed to purchase certain inventory and equipment related to MultiCell's Fa2N-4 cell line business, hire certain MultiCell scientific personnel, and pay for access to MultiCell's laboratories during transfer of the Fa2N-4 cell lines to Corning. MultiCell will retain and continue to support all of its existing licensees, including Pfizer, Bristol-Myers Squibb, and Eisai. MultiCell retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to produce therapeutic proteins using the Company's BioFactories(TM) technology, to identify drug targets and for other applications related to the Company's internal drug development programs. "We are pleased to partner with Corning in the drug discovery assay tools, ADME/Tox and biomarker segments. MultiCell's focus is on using our therapeutic antibody and Toll-like receptor (TLR) technologies to develop new drug candidates, and to advance our lead drug candidate, MCT-125, for the treatment of primary MS-related fatigue," said Jerry Newmin, Chairman of the Board of MultiCell Technologies. The foregoing events are further described in a Current Report on Form 8-K that Multicell Technologies filed on October 10, 2007 with the Securities and Exchange Commission. Snip Bernard

To: Jibacoa who wrote (1713)	11/7/2007 10:03:52 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

KOOL wants to start the day with the Rt. foot in spite of the general market & the fact that is due to report its 1stQ results at 5PM. bigcharts.marketwatch.com Last month the Cord Blood Registry announced that the FDA had issued a formal 510(k) clearance of the AutoXpress stem cell processing platform, which is the first and only automated processing technology with FDA clearance that can process cord blood collections of any size in a closed environment using sterile materials.(That is in spite of some problems with the system, which are been corrected.<g>) Actually,the published data shows that AXP consistently delivers the highest stem cell recovery rates in the industry. KOOL seems to have found support at the $2.10 level. bigcharts.marketwatch.com In spite of the losses in 2007 & the lower revenues in the 4thQ , things are expected to get better.<g> The short interest increased almost 70% in the last month & is around 18x its ADV. KOOL has no significant LTD, it has a pretty good institutional following with some high quality funds reportedly holding a substantial amount of the float. finance.yahoo.com Bottom line,it seems the R/R is OK at present levels, but I think I will wait for today's report & C.C.<g> bigcharts.marketwatch.com Bernard